Market Overview

HeartWare Sees Q4 Sales ~$32M

Share:
Related HTWR
Contemporary Results From Commercial HVAD System Registries Highlighted At ISHLT Meeting
18 Biotech Stocks These Wall Street Analysts Are Tracking

HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it expects total revenues for the fourth quarter of 2012 will be approximately $32 million, bringing expected full-year 2012 revenues to approximately $110 million.

Posted-In: News Guidance

 

Related Articles (HTWR)

Around the Web, We're Loving...

Get Benzinga's Newsletters